{
    "clinical_study": {
        "@rank": "136092", 
        "arm_group": [
            {
                "arm_group_label": "Intervention - internet reminder survey", 
                "arm_group_type": "Experimental", 
                "description": "Treatment phase is 12 months. During the intervention, each subject will receive fluocinonide 0.05% ointment, a standard treatment for psoriasis. If their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed in a small jar with a MEMS\u00ae electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. They will be asked to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed. They will receive weekly surveys via internet to complete."
            }, 
            {
                "arm_group_label": "Standard of care, no internet survey", 
                "arm_group_type": "Experimental", 
                "description": "Standard treatment for psoriasis. If it is felt that their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed to the subjects in a small jar with a MEMS\u00ae electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. All subjects will be assigned to treatment with topical fluocinonide to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate whether participation in an Internet-based intervention helps improve short-term\n      and long-term psoriasis treatment outcomes, in particular, adherence."
        }, 
        "brief_title": "Using an Internet Study to Improve Adherence for Psoriasis Patients", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "detailed_description": {
            "textblock": "An investigator-blinded, prospective study of subjects with mild to moderate psoriasis will\n      be conducted. Forty subjects ages 18 years and older will be enrolled.The Internet-based\n      survey will be piloted to evaluate its effect on adherence to topical psoriasis medication.\n      Subjects randomized in a 1:1 ratio to the Internet-survey group will log their impression of\n      the state of their psoriasis on a weekly basis. Subjects in both the intervention and\n      control groups will receive standard-of-care topical fluocinonide 0.05% ointment to be\n      applied to affected areas on the skin twice daily. Adherence to fluocinonide will be\n      assessed using Medication Event Monitoring System (MEMS\u00ae) caps, electronic monitors affixed\n      to the medication containers. Investigators and subjects will be blinded to the adherence\n      data until the final (Month 12) treatment visit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Any male or female 18 years or older of age with a diagnosis of mild to moderate\n             psoriasis by a dermatologist will be eligible for participation.\n\n          -  Less than 20% of body surface involvement for psoriasis.\n\n          -  Subject is capable of understanding and willing to provide a signed and dated written\n             voluntary informed consent before any protocol specific procedures are performed.\n\n          -  The subject is able to complete the study and comply with study instructions,\n             including attending all study visits.\n\n          -  In general good health with no other skin disease, disease state or physical\n             condition which would impair evaluation of psoriasis or which would increase health\n             risk by study participation\n\n        Exclusion Criteria:\n\n          -  Individuals younger than 18 years of age.\n\n          -  Known allergy or sensitivity to topical fluocinonide.\n\n          -  Inability to complete all study-related visits, or inability to complete the Internet\n             survey due to inadequate Internet access.\n\n          -  Introduction of any other prescription medication, topical or systemic, for psoriasis\n             while participating in the study. Subjects who are on systemic anti-inflammatory\n             treatments for psoriasis must be on a stable dose for at least 3 months prior to\n             enrollment.\n\n          -  Any skin condition or disease that may require concurrent therapy or may confound\n             evaluations\n\n          -  Current enrollment in any research study involving an investigational drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802580", 
            "org_study_id": "IRB00021783"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intervention - internet reminder survey", 
                "intervention_name": "Internet Survey", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": [
                    "Intervention - internet reminder survey", 
                    "Standard of care, no internet survey"
                ], 
                "intervention_name": "fluocinonide 0.05% ointment", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Fluonex", 
                    "Lonide", 
                    "Lyderm", 
                    "Fluocinonide-E", 
                    "Lidex", 
                    "Lidex-E", 
                    "Vanos", 
                    "Licon", 
                    "Dermacin", 
                    "Fluex"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fluocinonide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "contact": {
                "email": "sdowd@wakhealth.edu", 
                "last_name": "Susie C Dowd", 
                "phone": "336-716-3775"
            }, 
            "contact_backup": {
                "email": "irichard@wakehealth.edu", 
                "last_name": "Irma M Richardson, MHA", 
                "phone": "336-716-2903"
            }, 
            "facility": {
                "address": {
                    "city": "Winston Salem", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27157"
                }, 
                "name": "Wake Forest School of Medicine - Dermatology Clinic"
            }, 
            "investigator": {
                "last_name": "Steven R Feldman, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Using an Internet Study to Improve Adherence for Psoriasis Patients", 
        "overall_contact": {
            "email": "sdowd@wakhealth.edu", 
            "last_name": "Susie C Dowd", 
            "phone": "336-716-3775"
        }, 
        "overall_official": {
            "affiliation": "Wake Forest School of Medicine", 
            "last_name": "Steven R Feldman, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The measured adherence (MEMS\u00ae) of the Internet survey group compared to the standard-of-care control group after one month (short-term assessment) and twelve months (long-term assessment) of commencing the study\nThe MEMS\u00ae cap incorporates a microprocessor into the bottle cap of a standard medication bottle. Each time the bottle is opened for at least 3 seconds, the time and date of the opening are recorded. Subjects will be asked to bring the unused portion of the medication jar to each visit so that the medication can be \"weighed and refilled\". At each visit the information will be downloaded via the MEMS\u00ae communicator onto a computer database.", 
            "measure": "Measured MEMS Adherence", 
            "safety_issue": "No", 
            "time_frame": "1 month, 3 months, 6 monthhs, 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802580"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wake Forest School of Medicine", 
            "investigator_full_name": "Steven R. Feldman", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The measured adherence by the MEMS\u00ae cap in relation to the patient reported adherence via the Internet survey.\nThe MEMS\u00ae cap incorporates a microprocessor into the bottle cap of a standard medication bottle. Each time the bottle is opened for at least 3 seconds, the time and date of the opening are recorded. Subjects will be asked to bring the unused portion of the medication jar to each visit so that the medication can be \"weighed and refilled\". At each visit the information will be downloaded via the MEMS\u00ae communicator onto a computer database.", 
                "measure": "MEMS cap relation to internet survey", 
                "safety_issue": "No", 
                "time_frame": "1 month, 3 months, 6 months, 12 months"
            }, 
            {
                "description": "The change (dynamic assessment) from baseline visit to each return visit (or end of treatment) in the Psoriasis Area Severity Index and Investigator's Global Assessment.\nInvestigator's Global Assessment (IGA): Similar to assessment performed in clinical practice, based on a 6-point scale from 0 (completely clear) to 5 (very severe). Treatment success is defined as score of 0 or 1 (clear or almost clear).\nPsoriasis Area and Severity Index (PASI): The Psoriasis Area and Severity Index is commonly used in clinical trials as a granular measure of disease severity.  It is weighted for area in each of the four body regions and scores erythema, induration and desquamation on an overall scale from 0-72. Treatment success is defined as a 75% reduction in PASI score from baseline value.", 
                "measure": "Disease Severity with PASI and IGA assessment", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, 1 month, 3 months, 6 months, 12 months"
            }, 
            {
                "description": "The measured adherence by the MEMS\u00ae cap in relation to the change (dynamic assessment) in the Psoriasis Area Severity Index and Investigator's Global Assessment.", 
                "measure": "MEMs cap data compared to PASI and IGA Assessment", 
                "safety_issue": "No", 
                "time_frame": "1 month, 3  months, 6 months,12 months"
            }
        ], 
        "source": "Wake Forest School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wake Forest School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}